Inherited lipid metabolism disorder
MONDO:0002525An inherited metabolic disorder caused by an enzyme deficiency, resulting in an inability to oxidize fatty acids for energy production.
Also known as: disorder of lipid metabolism, dyslipidaemia, dyslipidemia, lipid metabolism disorder, fatty acid metabolism disorder
644 clinical trials for this condition and its sub-types, 201 tagged with Inherited lipid metabolism disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Inherited lipid metabolism disorder
-
Lysosomal lipid storage disorder 2 trials · 192 incl. sub-types
7 sub-types
- Sphingolipidosis 6 trials · 166 incl. sub-types Sub-types →
- Cerebral lipidosis with dementia 0 trials · 38 incl. sub-types Sub-types →
- Neuronal ceroid lipofuscinosis 6 trials · 23 incl. sub-types Sub-types →
- Xanthomatosis 2 trials · 8 incl. sub-types Sub-types →
- Lysosomal acid lipase deficiency 4 trials · 6 incl. sub-types Sub-types →
- Neutral lipid storage disease 1 trial · 2 incl. sub-types Sub-types →
- Triglyceride storage disease 0 trials Sub-types →
-
Familial hyperlipidemia 8 trials · 130 incl. sub-types
10 sub-types
- Familial hypercholesterolemia 58 trials · 94 incl. sub-types Sub-types →
- Hyperlipidemia, familial combined, LPL related 22 trials
- Familial lipoprotein lipase deficiency 6 trials
- Hyperlipoproteinemia type 3 4 trials
- Hyperlipoproteinemia type V 2 trials
- Cholesterol-ester transfer protein deficiency 0 trials
- Familial apolipoprotein C-II deficiency 0 trials
- Hyperlipidemia due to hepatic triglyceride lipase deficiency 0 trials
- Hyperlipidemia, combined, 2 0 trials
- Hyperlipoproteinemia, type 1D 0 trials
-
Syndromic dyslipidemia 0 trials · 73 incl. sub-types
29 sub-types
- CHILD syndrome 37 trials
- Smith-Lemli-Opitz syndrome 6 trials
- Cerebrotendinous xanthomatosis 6 trials
- Familial lipoprotein lipase deficiency 6 trials
- Lysosomal acid lipase deficiency 4 trials · 6 incl. sub-types Sub-types →
- Barth syndrome 5 trials
- Mevalonate kinase deficiency 3 trials · 4 incl. sub-types Sub-types →
- GM1 gangliosidosis type 1 3 trials
- Sjogren-Larsson syndrome 3 trials
- Nephrotic syndrome 14 3 trials
- Apparent mineralocorticoid excess 1 trial
- Neuronal ceroid lipofuscinosis 8 northern epilepsy variant 1 trial
- Peroxisome biogenesis disorder due to PEX5 defect in the PEX7-binding domain 0 trials · 1 incl. sub-types Sub-types →
- Rhizomelic chondrodysplasia punctata type 1 1 trial
- CHIME syndrome 0 trials
- Krabbe disease due to saposin A deficiency 0 trials
- PHARC syndrome 0 trials
- Autosomal recessive complex spastic paraplegia due to kennedy pathway dysfunction 0 trials
- Congenital ichthyosis-intellectual disability-spastic quadriplegia syndrome 0 trials
- Familial apolipoprotein C-II deficiency 0 trials
- Fatty acid hydroxylase-associated neurodegeneration 0 trials
- Hereditary spastic paraplegia 39 0 trials Sub-types →
- Hyperlipoproteinemia, type 1D 0 trials
- Hyperphosphatasia-intellectual disability syndrome 0 trials Sub-types →
- Intellectual disability, autosomal recessive 53 0 trials
- Lipoprotein glomerulopathy 0 trials
- Multiple congenital anomalies-hypotonia-seizures syndrome 2 0 trials
- Sea-blue histiocyte syndrome 0 trials
- Sitosterolemia 0 trials Sub-types →
-
Sterol metabolism disorder 0 trials · 60 incl. sub-types
4 sub-types
- Sterol biosynthesis disorder 0 trials · 45 incl. sub-types Sub-types →
- Cholesterol metabolism disease 3 trials · 13 incl. sub-types Sub-types →
- Inborn disorder of bile acid synthesis 2 trials · 12 incl. sub-types Sub-types →
- Recessive X-linked ichthyosis 2 trials Sub-types →
-
Steroid inherited metabolic disorder 0 trials · 39 incl. sub-types
3 sub-types
- Congenital adrenal hyperplasia 36 trials · 38 incl. sub-types Sub-types →
- Congenital bile acid synthesis defect 1 trial · 2 incl. sub-types Sub-types →
- Apparent mineralocorticoid excess 1 trial
-
Inherited fatty acid metabolism disorder 7 trials · 21 incl. sub-types
3 sub-types
- Disorder of fatty acid oxidation and ketogenesis 1 trial · 16 incl. sub-types Sub-types →
- Carnitine palmitoyl transferase 1A deficiency 1 trial
- Inherited lipoic acid biosynthesis defect 0 trials · 1 incl. sub-types Sub-types →
-
Disorder of phospholipids, sphingolipids and fatty acids biosynthesis 0 trials · 15 incl. sub-types
17 sub-types
- Barth syndrome 5 trials
- Sjogren-Larsson syndrome 3 trials
- Nephrotic syndrome 14 3 trials
- Hereditary sensory and autonomic neuropathy type 1 0 trials · 2 incl. sub-types Sub-types →
- Neutral lipid storage disease 1 trial · 2 incl. sub-types Sub-types →
- 3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome 0 trials
- GM3 synthase deficiency 0 trials
- PHARC syndrome 0 trials
- Sengers syndrome 0 trials
- Autosomal recessive complex spastic paraplegia due to kennedy pathway dysfunction 0 trials
- Congenital ichthyosis-intellectual disability-spastic quadriplegia syndrome 0 trials
- Fatty acid hydroxylase-associated neurodegeneration 0 trials
- Hereditary spastic paraplegia 39 0 trials Sub-types →
- Megaconial type congenital muscular dystrophy 0 trials
- Progressive encephalopathy with leukodystrophy due to DECR deficiency 0 trials
- Progressive myoclonic epilepsy type 8 0 trials
- Spinocerebellar ataxia type 38 0 trials
-
Hypolipoproteinemia 2 trials · 7 incl. sub-types
3 sub-types
- Hypobetalipoproteinemia 2 trials · 3 incl. sub-types Sub-types →
- Norum disease 2 trials
- Tangier disease 0 trials
-
Glucocorticoid resistance 3 trials
-
2 sub-types
-
CYP7B1-related disorder of oxysterol accumulation 0 trials · 2 incl. sub-types
2 sub-types
- Hereditary spastic paraplegia 5A 2 trials
- Congenital bile acid synthesis defect 3 0 trials
-
Disorder of plasmalogens biosynthesis 0 trials · 2 incl. sub-types
5 sub-types
- Rhizomelic chondrodysplasia punctata 2 trials Sub-types →
- Acyl-CoA binding domain containing protein 5 deficiency 1 trial
- Alkylglycerone-phosphate synthase deficiency 0 trials · 1 incl. sub-types Sub-types →
- Glyceronephosphate O-acyltransferase deficiency 0 trials · 1 incl. sub-types Sub-types →
- Fatty acyl-CoA reductase defects 0 trials Sub-types →
-
Inborn disorder of ketolysis 0 trials · 1 incl. sub-types
2 sub-types
-
Cortisone reductase deficiency 0 trials
2 sub-types
- Cortisone reductase deficiency 1 0 trials
- Cortisone reductase deficiency 2 0 trials
-
8 sub-types
- CHIME syndrome 0 trials
- GM3 synthase deficiency 0 trials
- Hypercoagulability syndrome due to glycosylphosphatidylinositol deficiency 0 trials
- Hyperphosphatasia-intellectual disability syndrome 0 trials Sub-types →
- Intellectual disability, autosomal recessive 53 0 trials
- Multiple congenital anomalies-hypotonia-seizures syndrome 1 0 trials
- Multiple congenital anomalies-hypotonia-seizures syndrome 2 0 trials
- Multiple congenital anomalies-hypotonia-seizures syndrome 3 0 trials
-
Lipoid proteinosis 0 trials
-
2 sub-types
- Combined pancreatic lipase-colipase deficiency 0 trials
- Pancreatic colipase deficiency 0 trials
Most studied deeper sub-types
-
Can a One-Time gene therapy fix fabry disease for years?
Cure Stopped earlyThis study follows people with Fabry disease who have already received FLT190, an experimental gene therapy that delivers a working copy of the GLA gene. The goal is to see how safe the treatment is over the long term and whether its effects last. Researchers will track participa…
Phase 1/2 • Sponsor: Spur Therapeutics • Aim: Cure
Last updated Sep 05, 2026 00:00 UTC
-
Can a single gene infusion rewrite the story of fabry disease?
Cure Stopped earlyThis trial is testing a gene therapy called FLT190 in adult men with classic Fabry disease, a genetic condition that causes harmful fat buildup in cells. The therapy uses a modified virus to deliver a working copy of the faulty gene, potentially enabling the body to produce the m…
Phase 1/2 • Sponsor: Spur Therapeutics • Aim: Cure
Last updated Sep 05, 2026 00:00 UTC
-
Experimental drug targets stubborn cholesterol in rare disease
Disease control Stopped earlyThis study tested an experimental drug called ARO-ANG3 in 18 people with homozygous familial hypercholesterolemia (HoFH), a rare genetic condition causing extremely high cholesterol. Participants received injections of the drug and were monitored for safety and cholesterol change…
Phase 2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental drug for cholesterol and fatty liver fails to advance
Disease control Stopped earlyThis early-stage trial tested a new drug called LY3885125 in people with high cholesterol (dyslipidemia) and non-alcoholic fatty liver disease (NAFLD). The main goal was to check safety and how the body processes the drug. The study was terminated, meaning it stopped early, so it…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Hope fades: trial of Tay-Sachs drug venglustat terminated early
Disease control Stopped earlyThis Phase 3 trial tested an oral drug called venglustat in 75 adults and children with late-onset Tay-Sachs or Sandhoff disease, rare genetic disorders that cause progressive nerve damage. The drug aimed to lower toxic fat buildup in the brain and slow disease worsening. However…
Phase 3 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for kids with rare hormone disorder: drug may cut steroid doses
Disease control Stopped earlyThis study tested an experimental drug called tildacerfont in 67 children aged 2 to 17 with congenital adrenal hyperplasia (CAH), a genetic condition that disrupts hormone production. The goal was to see if adding this once-daily pill to standard steroid treatment could improve d…
Phase 2 • Sponsor: Spruce Biosciences • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Prostate cancer drug trialed to reduce steroids in kids with rare hormone disorder
Disease control Stopped earlyThis early-phase study tested a drug called abiraterone acetate (normally used for prostate cancer) in 4 children with congenital adrenal hyperplasia (CAH). The goal was to see if it could lower high male hormone levels and reduce the need for strong steroid medications that can …
Phase 1 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Experimental cell therapy targets deadly childhood brain cancer
Disease control Stopped earlyThis early-phase trial tested a new immunotherapy approach for children with DIPG, a rare and aggressive brain stem tumor. After standard radiation and chemotherapy, patients received special vaccines and immune cells designed to attack the tumor. The study was small (11 particip…
Phase 1 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug aims to cut steroid use in rare hormone disorder
Disease control Stopped earlyThis study tested a daily tablet called Tildacerfont in 100 adults with classic congenital adrenal hyperplasia, a condition where the body can't make certain hormones properly. The goal was to see if the drug could safely reduce the high doses of steroids patients need to take. T…
Phase 2 • Sponsor: Spruce Biosciences • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Heart drug for diabetics shows promise but trial ends early
Disease control Stopped earlyThis study tested whether pemafibrate, a drug that lowers triglycerides, could reduce heart attacks, strokes, and heart-related deaths in over 10,000 people with type 2 diabetes and high triglycerides. Participants took either pemafibrate or a placebo twice daily. The trial was t…
Phase 3 • Sponsor: Kowa Research Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Experimental drug zavesca tested for rare fatal brain diseases in infants
Disease control Stopped earlyThis phase 3 trial tested the drug miglustat (Zavesca) in 30 infants with Sandhoff or Tay-Sachs diseases, rare genetic disorders that destroy nerve cells. The goal was to see if the drug could reduce hospitalizations, seizures, and feeding problems while improving motor function.…
Phase 3 • Sponsor: Tehran University of Medical Sciences • Aim: Disease control
Last updated Jun 26, 2026 17:51 UTC
-
Experimental gene therapy targets Tay-Sachs and sandhoff in kids
Disease control Stopped earlyThis early-stage trial tested a gene therapy called AXO-AAV-GM2 in children with Tay-Sachs or Sandhoff disease, rare and fatal genetic brain disorders. The therapy delivers healthy genes directly into the brain and spinal fluid to try to restore a missing enzyme. The study was te…
Phase 1 • Sponsor: Terence Flotte • Aim: Disease control
Last updated Jun 26, 2026 13:03 UTC
-
Home infusions may help patients stick to treatment
Knowledge-focused Stopped earlyThis study looks at whether people with Fabry, Gaucher, or Hunter disease are more likely to continue their IV treatment when it's given at home versus at a hospital. Researchers will review existing data from 222 patients in Mexico. No new treatments are given; the goal is to un…
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Scientists dive into rare cholesterol disorders to uncover clues
Knowledge-focused Stopped earlyThis study looks at rare genetic disorders where the body can't make cholesterol properly, which can cause birth defects and learning problems. Researchers collect blood, urine, and tissue samples from affected people and their families to learn more about these conditions. The g…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Russian study seeks hidden cases of rare liver disease in kids
Knowledge-focused Stopped earlyThis study looks at children and teens in Russia who may have a rare genetic condition called lysosomal acid lipase deficiency (LAL-D). Researchers will check for the disease in up to 1,200 participants using blood tests and genetic testing. The goal is to understand how often LA…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
Fabry disease sperm study halted early
Knowledge-focused Stopped earlyThis study aimed to find out how common sperm problems are in men with Fabry disease. Researchers planned to check sperm samples from 22 men aged 18 to 65. The study was stopped early, so results are limited.
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Superhero training for food allergy safety falls short
Knowledge-focused Stopped earlyThis study aimed to help children aged 6-8 from low-income families learn how to avoid foods they are allergic to. The program used fun, hands-on activities to teach safety skills. The study was stopped early, so we don't have clear results on whether it worked.
Sponsor: Kent State University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Gene therapy for krabbe disease: did it last?
Knowledge-focused Stopped earlyThis study follows up on children with Krabbe disease who received a one-time gene therapy infusion (FBX-101) in earlier trials. Researchers will monitor safety and measure motor skills over time. Only 2 participants are enrolled, so results are very limited.
Sponsor: Forge Biologics, Inc • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:47 UTC